Anakinra therapy in a child with systemic-onset juvenile rheumatoid arthritis after human herpesvirus 6 encephalitis.
A 3-year-old patient with biopsy-proven herpesvirus 6 (HHV-6) encephalitis developed a clinical condition consistent with systemic-onset juvenile idiopathic rheumatoid arthritis (SoJIA) and responsive to synthetic interleukin-1 (IL-1) receptor therapy. This suggested both a temporal relationship between HHV-6 infection and the development of SoJIA and the likely involvement of IL-1 in his disease. This case adds to the current experience of IL-1 receptor antagonist therapy in SoJIA. In addition, it suggests that future prospective studies in new-onset SoJIA should include an evaluation for HHV-6 infection.
Mirkinson
Laura J
LJ
Department of Rheumatology, Children's National Medical Center, 111 Michigan Avenue NW, Washington, DC 20010, USA. mirkil@holycrosshealth.org
Nagle
David
D
Kadom
Nadja
N
Jones
Olcay Y
OY
D018501:Antirheumatic Agents / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use; D001171:Arthritis, Juvenile / Q000188:drug therapy* / Q000821:virology*; D002675:Child, Preschool; D018792:Encephalitis, Viral / Q000188:drug therapy / Q000821:virology; D005334:Fever / Q000188:drug therapy / Q000821:virology; D015774:Ganciclovir / Q000627:therapeutic use; D015654:Herpesvirus 6, Human / Q000302:isolation & purification; D006801:Humans; D053590:Interleukin 1 Receptor Antagonist Protein; D008297:Male; D017472:Receptors, Interleukin-1 / Q000037:antagonists & inhibitors; D019349:Roseolovirus Infections / Q000150:complications* / Q000188:drug therapy; D012795:Sialoglycoproteins / Q000627:therapeutic use*
D018501:Antirheumatic Agents; D000998:Antiviral Agents; C507763:IL1RN protein, human; D053590:Interleukin 1 Receptor Antagonist Protein; D017472:Receptors, Interleukin-1; D012795:Sialoglycoproteins; D015774:Ganciclovir